We are monitoring the impact of COVID-19 & Recession alarm on MEA Ovarian Cancer Market Get in touch with us for detailed analysis Know More
Share on

Middle East and Africa Ovarian Cancer Market Research Report – Segmented By Stage Of Cancer, Cancer Type, Diagnosis, Type Of Treatment & Country (KSA, UAE, Israel, rest of GCC countries, South Africa, Ethiopia, Kenya, Egypt, Sudan, rest of MEA) – Industry Analysis on Size, Share, Trends, COVID-19 Impact & Growth Forecast (2022 to 2027)

Published: January, 2022
ID: 1396
Pages: 181

MEA Ovarian Cancer Market Size (2022 to 2027)

The size of the Ovarian Cancer Market in the MEA region is estimated to grow at a sluggish CAGR between 2022 to 2027.

The increasing prevalence of ovarian cancer and the growing use of combination therapies for disease treatment primarily drive the ovarian cancer market in MEA. Ovarian cancer is more common in women between the ages of 55 and 64. The most frequent ovarian cancer symptoms are bloating, pelvic and abdominal discomfort, difficulty eating, and urine symptoms.

In addition, the technological advancements in the healthcare sector are boosting market growth. In addition, the introduction of effective therapies and advanced drugs, and favorable reimbursement policies are driving the market growth. 

Other factors such as growing awareness, increasing disposable income, and supportive government policies encourage market growth. Also, the rising initiatives for raising awareness about pre-diagnosing tests and benefits available in the market among people are expected to propel market growth. 

Due to the increase in the prevalence of population with growing elderly population especially women over age 50 have higher risk rates of developing ovarian cancer why may due to having any family history of having cancer which is caused due to inherited mutations in the specific genes is the primary cause that is driving the growth in the ovarian cancer market.

With the increase in the new advancement in the technology for developing reliable and efficient tests and therapies for diagnosing cancer in patients, the widely used equipment to test ovarian cancer is the Transvaginal ultrasound (TVUS), which uses high-energy sound waves to identify the presence of abnormalities such as an ovarian tumor. However, other tests are also available in the market which is used for diagnosing and detecting cancer.

The increasing investments by the government and non-government organizations in research and development activities to develop an advanced and effective treatment for cancer and other kinds of disease treatment.

Key players in the region are adopting various market strategies to gain competitiveness overhead the marketplace. The strategies include partnerships, mergers, and acquisitions. Also, these strategies strengthen the regional market expansion. 

However, the increase in the availability of various alternative drugs present in the market lack of skilled and trained individuals are also hampering the growth of the ovarian cancer market. Also, due to lack of awareness among the people about the pre-diagnosing effects, lack of proper technology and equipment for diagnosing or detecting early stages are limiting the ovarian cancer market in the MEA region.

This research report on the MEA ovarian cancer market has been segmented and sub-segmented into the following categories:

By Stage of Cancer:

  • Stage I
    • Stage IA
    • Stage IB
    • Stage IC
  • Stage II
    • Stage IIA
    • Stage IIB
    • Stage IIC
  • Stage III
    • Stage IIIA
    • Stage IIIB
    • Stage IIIC
  • Stage IV

By Cancer Type:

  • Primary Peritoneal Carcinoma
  • Ovarian Stromal Tumors
  • Ovarian Germ Cell Tumors
  • Epithelial Ovarian Tumors

By Diagnosis:

  • Physical Examination
  • Blood Tests
  • Ultrasound
  • PET
  • CT Scan
  • MRI
  • Human Chorionic Gonadotropin Test
  • Biopsy

By Type of Treatment:

  • Chemotherapy
  • Radiation Therapy
  • Hormonal Therapy
  • Surgery
  • Immunotherapy
  • Targeted Therapy

By Country:

  • KSA
  • UAE
  • Israel
  • rest of GCC countries
  • South Africa
  • Ethiopia
  • Kenya
  • Egypt
  • Sudan
  • rest of MEA

The Middle East and Africa market is expected to register a moderate share in the global ovarian cancer market during the forecast period. The regional market growth is attributed to the increase in the prevalence of ovarian cancer among the rising geriatric population and increasing healthcare spending. The major growth contributors in the region are South Africa, UAE, and Saudi Arabia.

UAE is expected to witness a significant share in the ovarian cancer market in the coming years. Increasing healthcare expenditure, establishing healthcare facilities, and an aging population is propelling the market growth.

South Africa accounted for the largest share of the Ovarian cancer market. The Proliferation of cancer drives the market growth; according to Globocan, in 2018, around 1,371 new ovarian cancer cases in South Africa, and about 971 people died due to this disease. Also, due to easing age- standardization rate of ovarian cancer is 3.9 per 100,000, as well as increasing initiatives and findings from government and non-government firms in research activities and raising awareness among the people about pre- diagnosing tests and medications available in the market, helps in driving the market growth for ovarian cancer.

KEY MARKET PLAYERS:

Some of the major players in this market are Aetera Zenteris Inc., Eli Lilly and Company, Roche, Amgen, Janssen Pharmaceuticals, Inc., Bristol Myers Squibb Company, Novogen, Inc., GlaxoSmithKline, Boehringer Ingelheim, AstraZeneca and Genentech Inc., Novogen, Inc., GlaxoSmithKline, Boehringer Ingelheim, AstraZeneca and Genentech Inc.       

1.Introduction                                  

                1.1 Market Definition                    

                1.2 Study Deliverables                  

                1.3 Base Currency, Base Year and Forecast Periods                           

                1.4 General Study Assumptions                

2. Research Methodology                                           

                2.1 Introduction                              

                2.2 Research Phases                      

                                2.2.1 Secondary Research            

                                2.2.2 Primary Research 

                                2.2.3 Econometric Modelling     

                                2.2.4 Expert Validation  

                2.3 Analysis Design                         

                2.4 Study Timeline                          

3. Overview                                      

                3.1 Executive Summary                

                3.2 Key Inferences                         

                3.3 Epidemology                             

4. Drivers, Restraints, Opportunities, and Challenges Analysis (DROC)                                      

                4.1 Market Drivers                          

                4.2 Market Restraints                    

                4.3 Key Challenges                         

                4.4 Current Opportunities in the Market               

5. Market Segmentation                                              

                5.1 Stage Of Cancer                        

                                5.1.1 Stage I       

                                                5.1.1.1 Stage IA

                                                5.1.1.2 Stage IB

                                                5.1.1.3 Stage IC

                                5.1.2 Stage II     

                                                5.1.2.1 Stage IIA

                                                5.1.2.2 Stage IIB

                                                5.1.2.3 Stage IIC

                                5.1.3 Stage III    

                                                5.1.3.1 Stage IIIA

                                                5.1.3.2 Stage IIIB

                                                5.1.3.3 Stage IIIC

                                5.1.4 Stage IV    

                                5.1.5 Y-o-Y Growth Analysis, By Stage Of Cancer

                                5.1.6 Market Attractiveness Analysis, By Stage Of Cancer               

                                5.1.7 Market Share Analysis, By Stage Of Cancer

                5.2 Type                              

                                5.2.1 Introduction           

                                5.2.2 Primary Peritoneal Carcinoma        

                                5.2.3 Ovarian Stromal Tumors   

                                5.2.4 Ovarian Germ Cell Tumors

                                5.2.5 Epithelial Ovarian Tumors

                                5.2.6 Y-o-Y Growth Analysis, By Type      

                                5.2.7 Market Attractiveness Analysis, By Type     

                                5.2.8 Market Share Analysis, By Type      

                5.3 Diagnosis                     

                                5.3.1 Introduction           

                                5.3.2 Physical Examination          

                                5.3.3 Blood Tests             

                                5.3.4 Ultrasound             

                                5.3.5 PET             

                                5.3.6 CT Scan     

                                5.3.7 MRI            

                                5.3.8 Human Chorionic Gonadotropin Test          

                                5.3.9 Biopsy       

                                5.3.10 Y-o-Y Growth Analysis, By Diagnosis          

                                5.3.11 Market Attractiveness Analysis, By Diagnosis         

                                5.3.12 Market Share Analysis, By Diagnosis          

                5.4 Treatment                  

                                5.4.1 Introduction           

                                5.4.2 Chemotherapy     

                                5.4.3 Radiation Therapy

                                5.4.4 Hormonal Therapy              

                                5.4.5 Surgery    

                                5.4.6 Immunotherapy   

                                5.4.7 Targeted Therapy

                                5.4.8 Y-o-Y Growth Analysis, By Treatment          

                                5.4.9 Market Attractiveness Analysis, By Treatment         

                                5.4.10 Market Share Analysis, By Treatment       

6. Geographical Analysis                                              

                6.1 Introduction                              

                                6.1.1 Regional Trends    

                                6.1.2 Impact Analysis     

                                6.1.3 Y-o-Y Growth Analysis        

                                                6.1.3.1 By Geographical Area

                                                6.1.3.2 By Stage of Cancer

                                                6.1.3.3 By Type

                                                6.1.3.4 By Diagnosis

                                                6.1.3.5 By Treatment

                                6.1.4 Market Attractiveness Analysis      

                                                6.1.4.1 By Geographical Area

                                                6.1.3.2 By Stage of Cancer

                                                6.1.3.3 By Type

                                                6.1.3.4 By Diagnosis

                                                6.1.3.5 By Treatment

                                6.1.5 Market Share Analysis        

                                                6.1.5.1 By Geographical Area

                                                6.1.3.2 By Stage of Cancer

                                                6.1.3.3 By Type

                                                6.1.3.4 By Diagnosis

                                                6.1.3.5 By Treatment

                6.2 Middle-East                                

                6.3 Africa                            

7.Strategic Analysis                                        

                7.1 PESTLE analysis                         

                                7.1.1 Political     

                                7.1.2 Economic 

                                7.1.3 Social         

                                7.1.4 Technological         

                                7.1.5 Legal          

                                7.1.6 Environmental      

                7.2 Porter’s Five analysis                              

                                7.2.1 Bargaining Power of Suppliers        

                                7.2.2 Bargaining Power of Consumers    

                                7.2.3 Threat of New Entrants     

                                7.2.4 Threat of Substitute Products and Services

                                7.2.5 Competitive Rivalry within the Industry      

8.Market Leaders' Analysis                                          

                8.1 Aetera Zenteris Inc.                

                                8.1.1 Overview

                                8.1.2 Product Analysis   

                                8.1.3 Financial analysis  

                                8.1.4 Recent Developments       

                                8.1.5 SWOT analysis       

                                8.1.6 Analyst View          

                8.2 Eli Lilly and Company                             

                8.3 Roche                           

                8.4 Amgen                         

                8.5 Janssen Pharmaceuticals, Inc.                             

                8.6 Bristol Myers Squibb Company                          

                8.7 Novogen, Inc.                            

                8.8 GlaxoSmithKline                      

                8.9 Boehringer Ingelheim                            

                8.10 AstraZeneca                            

                8.11 Genentech Inc.                       

9.Competitive Landscape                                            

                9.1 Market share analysis                            

                9.2 Merger and Acquisition Analysis                        

                9.3 Agreements, collaborations and Joint Ventures                          

                9.4 New Product Launches                          

10.Market Outlook and Investment Opportunities                                           

Appendix                                           

                a) List of Tables                

                b) List of Figures                              

  1. Middle East & Africa Ovarian Cancer Market, By Stage Of Cancer, From 2022 - 2027 (USD Million)
  2. Middle East & Africa Stage I Market, By Region, From 2022 - 2027 (USD Million)
  3. Middle East & Africa Stage II Market, By Region, From 2022 - 2027 (USD Million)
  4. Middle East & Africa Stage III Market, By Region, From 2022 - 2027 (USD Million)
  5. Middle East & Africa Stage IV Market, By Region, From 2022 - 2027 (USD Million)
  6. Middle East & Africa Ovarian Cancer Market, By Cancer Type, From 2022 - 2027 (USD Million)
  7. Middle East & Africa Primary Peritoneal Carcinoma Market, By Region, From 2022 - 2027 (USD Million)
  8. Middle East & Africa Ovarian Stromal Tumors Market, By Region, From 2022 - 2027 (USD Million)
  9. Middle East & Africa Ovarian Germ Cell Tumors Market, By Region, From 2022 - 2027 (USD Million)
  10. Middle East & Africa Epithelial Ovarian Tumors Market, By Region, From 2022 - 2027 (USD Million)
  11. Middle East & Africa Ovarian Cancer Market, By Diagnosis, From 2022 - 2027 (USD Million)
  12. Middle East & Africa Physical Examination Market, By Region, From 2022 - 2027 (USD Million)
  13. Middle East & Africa Blood Tests Market, By Region, From 2022 - 2027 (USD Million)
  14. Middle East & Africa Ultrasound Market, By Region, From 2022 - 2027 (USD Million)
  15. Middle East & Africa PET Market, By Region, From 2022 - 2027 (USD Million)
  16. Middle East & Africa CT Scan Market, By Region, From 2022 - 2027 (USD Million)
  17. Middle East & Africa MRI Market, By Region, From 2022 - 2027 (USD Million)
  18. Middle East & Africa Human Chorionic Gonadotropin Test Market, By Region, From 2022 - 2027 (USD Million)
  19. Middle East & Africa Biopsy Market, By Region, From 2022 - 2027 (USD Million)
  20. Middle East & Africa Ovarian Cancer Market, By Type Of Treatment, From 2022 - 2027 (USD Million)
  21. Middle East & Africa Chemotherapy Market, By Region, From 2022 - 2027 (USD Million)
  22. Middle East & Africa Radiation Therapy Market, By Region, From 2022 - 2027 (USD Million)
  23. Middle East & Africa Hormonal Therapy Market, By Region, From 2022 - 2027 (USD Million)
  24. Middle East & Africa Surgery Market, By Region, From 2022 - 2027 (USD Million)
  25. Middle East & Africa Immunotherapy Market, By Region, From 2022 - 2027 (USD Million)
  26. Middle East & Africa Targeted Therapy Market, By Region, From 2022 - 2027 (USD Million)
  27. Middle East Ovarian Cancer Market, By Stage Of Cancer, From 2022 - 2027 (USD Million)
  28. Middle East Ovarian Cancer Market, By Cancer Type, From 2022 - 2027 (USD Million)
  29. Middle East Ovarian Cancer Market, By Diagnosis, From 2022 - 2027 (USD Million)
  30. Middle East Ovarian Cancer Market, By Type Of Treatment, From 2022 - 2027 (USD Million)
  31. Africa Ovarian Cancer Market, By Stage Of Cancer, From 2022 - 2027 (USD Million)
  32. Africa Ovarian Cancer Market, By Cancer Type, From 2022 - 2027 (USD Million)
  33. Africa Ovarian Cancer Market, By Diagnosis, From 2022 - 2027 (USD Million)
  34. Africa Ovarian Cancer Market, By Type Of Treatment, From 2022 - 2027 (USD Million)

Please wait. . . . Your request is being processed

Related Reports

PURCHASE OPTIONS

excel
$

2875


pdf excel
$

3220


pdf excel powerbi
$

4600


excel
$

2000

What You Get :

  • PDF Report Format.
  • Can be accessible by 1 single user.
  • 6 Months of Free Analyst Support.
  • PDF and Excel Datasheet Formats.
  • Can be accessible upto 2 to 5 users.
  • 1 Year of Free Analyst Support.
  • PDF, Excel and Power BI Dashboard.
  • Can be accessible by unlimited users.
  • 1 Year of Free Analyst Support.
  • Excel Datasheet Format.
  • Customized access as per user request.
  • Upgradable to other licenses.
customer-support
ASK FOR CUSTOMIZATION

Talk to our analyst and get customised report done according to your research needs

tag
INQUIRE FOR DISCOUNT

Check if you can avail any discount. Submit your details and our team will get back to you.

cloud-download
DOWNLOAD FREE SAMPLE

Request to avail a free sample report that reflects this market and its growth.

Access the study in MULTIPLE FORMATS
Purchase options starting from $ 2875

Didn’t find what you’re looking for?
TALK TO OUR TEAM

Find it too expensive?
NO WORRIES!

Click for Request Sample